Alnylam Pharmaceuticals
ALNY
#447
Rank
โ‚ฌ44.64 B
Marketcap
337,90ย โ‚ฌ
Share price
-2.21%
Change (1 day)
45.14%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2025 (TTM): 0,006914ย โ‚ฌ

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is 0,07628ย โ‚ฌ. In 2023 the company made an earnings per share (EPS) of -2,99ย โ‚ฌ an increase over its 2022 EPS that were of -7,87ย โ‚ฌ.

EPS history for Alnylam Pharmaceuticals from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)0,006914ย โ‚ฌ
2023-2,99ย โ‚ฌ-62%
2022-7,87ย โ‚ฌ29.03%
2021-6,10ย โ‚ฌ-3.36%
2020-6,31ย โ‚ฌ-8.48%
2019-6,90ย โ‚ฌ7.67%
2018-6,41ย โ‚ฌ39.74%
2017-4,58ย โ‚ฌ12.94%
2016-4,06ย โ‚ฌ38.84%
2015-2,92ย โ‚ฌ-32.88%
2014-4,36ย โ‚ฌ259.44%
2013-1,21ย โ‚ฌ-31.25%
2012-1,76ย โ‚ฌ

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Arrowhead Pharmaceuticals
ARWR
-1,06ย โ‚ฌ-1,488.89%๐Ÿ‡บ๐Ÿ‡ธ USA
Regeneron Pharmaceuticals
REGN
36,82ย โ‚ฌ 48,166.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-2,32ย โ‚ฌ-3,144.44%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-0,20ย โ‚ฌ-366.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-0,62ย โ‚ฌ-911.11%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
6,24ย โ‚ฌ 8,077.78%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
3,14ย โ‚ฌ 4,017.43%๐Ÿ‡ซ๐Ÿ‡ท France
Teva Pharmaceutical Industries
TEVA
0,53ย โ‚ฌ 600.00%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel